Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056843 | 0.90 | CYP2C19 (0.60) | MGLLENPP2RAB9ANPC1MAPT | |
| SCHEMBL6166293 | 0.88 | PTPN1 (0.61) | MGLLENPP2RAB9ANPC1HDAC1 | |
| SCHEMBL1095126 | 0.82 | CASP3 (0.58) | MGLLRAB9ANPC1CYP1A2CYP2C19 | |
| SCHEMBL6162827 | 0.81 | MAOB (0.43) | MGLLENPP2RAB9ANPC1MAPT | |
| SCHEMBL10874779 | 0.81 | NPC1 (0.68) | RAB9ANPC1MAPTCYP1A2CYP2C19 | |
| SCHEMBL27608693 | 0.80 | MGLL (0.54) | MGLLENPP2RAB9ANPC1HDAC1 | |
| SCHEMBL5055502 | 0.80 | NPC1 (0.58) | MGLLENPP2RAB9ANPC1EPHX1 | |
| SCHEMBL27608697 | 0.80 | ENPP2 (0.65) | MGLLENPP2RAB9ANPC1HDAC1 | |
| SCHEMBL1800596 | 0.79 | ALDH1A1 (0.54) | MAPTCYP1A2CYP2C19PTPN1KMT2A | |
| SCHEMBL3793285 | 0.79 | MGLL (0.63) | MGLLENPP2RAB9ANPC1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379516-B1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-6903086-B2 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-06-07 | — | — | US | disclosed |
| EP-1379516-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002070500-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | GPBAR1, GABRP, TBXA2R | MGLL 1914/4885ENPP2 327/4885RAB9A 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.